BioNTech SE

🔬 𝐁𝐢𝐨𝐍𝐓𝐞𝐜𝐡 𝐚𝐭 𝐀𝐒𝐂𝐎 𝐀𝐧𝐧𝐮𝐚𝐥 𝐌𝐞𝐞𝐭𝐢𝐧𝐠 𝟐𝟎𝟐𝟒 We are excited to present updates for selected programs of our immuno-oncology pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 in Chicago. This year’s presentations feature updates across all three key pillars of our diversified oncology pipeline, including novel #immunomodulators, targeted therapies such as CAR-T cell therapy candidates, and therapeutic #mRNA cancer vaccines.   Our aim with our modality-agnostic toolbox is to develop innovative treatment options across the continuum of #cancer disease and establish new treatment paradigms that have the potential to address the fundamental challenges of treating cancer with the aim to drive meaningful improvements in the long-term survival rates for patients. 𝐅𝐢𝐧𝐝 𝐨𝐮𝐭 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐨𝐮𝐫 𝐮𝐩𝐝𝐚𝐭𝐞𝐬 𝐭𝐨 𝐛𝐞 𝐩𝐫𝐞𝐬𝐞𝐧𝐭𝐞𝐝 𝐚𝐭 #𝐀𝐒𝐂𝐎𝟐𝟒. 👇 𝑹𝒆𝒂𝒅 𝒎𝒐𝒓𝒆: https://lnkd.in/ePCjpgJu

+++ 𝗔𝗻𝗻𝘂𝗮𝗹 𝗚𝗲𝗻𝗲𝗿𝗮𝗹 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝟮𝟬𝟮𝟰 +++ We have just concluded our #AGM2024. All resolutions proposed on the agenda items put to the vote today at the AGM were approved by a large majority of the shareholders. “2023 was a year in which we made important progress in many areas: We maintained a leading position in the COVID-19 vaccine market, published encouraging data for candidates in our oncology pipeline and launched potentially registrational trials. Additionally, we have strengthened our organization in preparation for the next phase of growth, particularly with regards to our planned product launches in oncology,” said our CEO and Co-Founder Ugur Sahin. “We are convinced that our therapies under development, if approved, have the potential to complement established cancer treatment approaches in many areas in the future.” The detailed voting results for all agenda items can be viewed on our website under the following link: https://lnkd.in/eqczZUJ6 𝙇𝙞𝙣𝙠 𝙩𝙤 𝙥𝙧𝙚𝙨𝙨 𝙧𝙚𝙡𝙚𝙖𝙨𝙚 𝙖𝙣𝙙 𝙛𝙤𝙧𝙬𝙖𝙧𝙙-𝙡𝙤𝙤𝙠𝙞𝙣𝙜 𝙨𝙩𝙖𝙩𝙚𝙢𝙚𝙣𝙩𝙨: https://lnkd.in/eamehhH2 

+++ 𝗤𝟭 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝟮𝟬𝟮𝟰 𝗮𝗻𝗱 𝗰𝗼𝗿𝗽𝗼𝗿𝗮𝘁𝗲 𝘂𝗽𝗱𝗮𝘁𝗲 +++ We started the year with good progress across our oncology pipeline and our commercialization activities. Some key events: 🔬 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆: We and our collaboration partner Duality Biologics dosed the first patient in a Phase 3 clinical trial with our #ADC candidate BNT323/DB-1303 in breast cancer patients, advancing towards BioNTech’s goal of ten or more potentially registrational trials running by the end of 2024. 🩹 𝗖𝗢𝗩𝗜𝗗-𝟭𝟵: We are focusing on preparing for variant-strain adaptation of our COVID-19 vaccine to be ready for a commercial launch ahead of the upcoming 2024/2025 vaccination season, pending approvals. 🌎 𝗖𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹 𝗿𝗲𝗮𝗱𝗶𝗻𝗲𝘀𝘀: We appointed our General Manager Fatma Ocak for the U.S. in line with our commercial preparations to drive our first expected global #oncology product launch. 𝗟𝗶𝗻𝗸 𝘁𝗼 𝗣𝗥 𝗮𝗻𝗱 𝗳𝗼𝗿𝘄𝗮𝗿𝗱-𝗹𝗼𝗼𝗸𝗶𝗻𝗴 𝘀𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁𝘀: https://lnkd.in/ePDQiHbH  

+++ 𝐌𝐞𝐞𝐭 𝐁𝐢𝐨𝐍𝐓𝐞𝐜𝐡’𝐬 𝐩𝐢𝐨𝐧𝐞𝐞𝐫𝐬: 𝐄𝐬𝐭𝐡𝐞𝐫 𝐍𝐝𝐚𝐦𝐛𝐢𝐫𝐢 +++ “I want to leave a legacy where I have solved a problem, no matter how small within my community,” says Esther Ndambiri. At BioNTech, where multiple teams are working jointly to contribute to equitable access to novel medicines worldwide, she has found a place in the industry to work towards her goal. 𝐂𝐨𝐦𝐦𝐢𝐭𝐭𝐞𝐝 𝐭𝐨 𝐢𝐦𝐩𝐫𝐨𝐯𝐞 𝐭𝐡𝐞 𝐡𝐞𝐚𝐥𝐭𝐡 𝐨𝐟 𝐩𝐞𝐨𝐩𝐥𝐞 𝐰𝐨𝐫𝐥𝐝𝐰𝐢𝐝𝐞 Esther is part of #TeamBioNTech’s Global Health Office (GHO). Together with the clinical development team, the GHO focuses on health challenges such as tuberculosis, malaria, and HIV, which affect millions worldwide and are especially prevalent in lower-income countries. To achieve our goal of running clinical trials in these three indications on the African continent by the end of 2024, the team supports the pre-clinical and clinical development of our infectious disease vaccine portfolio by  building, managing, and fostering strategic partnerships with key stakeholders. They aim to establish the capabilities needed to develop and deliver novel medicines and aspire to pave the way for improved healthcare access and outcomes, pandemic preparedness, and ultimately work towards our vision to improve the health of people worldwide. #humanlypossible We are looking for fellow pioneers to help us shape the future of global health. 𝑶𝒑𝒑𝒐𝒓𝒕𝒖𝒏𝒊𝒕𝒊𝒆𝒔 𝒂𝒕 #𝑻𝒆𝒂𝒎𝑩𝒊𝒐𝑵𝑻𝒆𝒄𝒉: https://lnkd.in/dFN2BQPq

+++ 𝐎𝐮𝐫 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐭𝐡𝐫𝐢𝐯𝐞𝐬 𝐨𝐧 𝐬𝐜𝐢𝐞𝐧𝐭𝐢𝐟𝐢𝐜 𝐚𝐧𝐝 𝐦𝐞𝐝𝐢𝐜𝐚𝐥 𝐞𝐱𝐜𝐡𝐚𝐧𝐠𝐞 +++ At #BioNTech, we are dedicated to pioneering advances in #vaccine research and development. Our goal is to not only to develop vaccine candidates to address pathogens with high medical need, but to continuously evolve and adapt to the changing landscape of infectious diseases. Part of this process is the ongoing exchange with the scientific and medical community. Together with our partners and a great team of investigators, we are constantly researching vaccine candidates against diseases such as malaria, tuberculosis and HIV and are further developing our candidates against respiratory diseases such as COVID-19, with the aim of being at the forefront in tackling these health threats. 𝐂𝐨𝐧𝐬𝐭𝐚𝐧𝐭 𝐜𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧 𝐰𝐢𝐭𝐡 𝐩𝐡𝐲𝐬𝐢𝐜𝐢𝐚𝐧𝐬 𝐚𝐧𝐝 𝐬𝐜𝐢𝐞𝐧𝐭𝐢𝐬𝐭𝐬 Working together and engaging in dialog with physicians and scientists are important pillars in working towards this goal. Participating in forums such as the #DGIM congress of Deutsche Gesellschaft für Innere Medizin e.V. enables us to exchange ideas, share insights and thus work to stay at the forefront of medical progress and scientific exchange. We are excited about the opportunities to connect with the scientific and medical community and share our progress as we continue our journey to translate #science into survival and aiming to contribute to improve the #health of people worldwide!

+++ 𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐮𝐩𝐝𝐚𝐭𝐞: 𝐓𝐡𝐫𝐞𝐞-𝐲𝐞𝐚𝐫 𝐏𝐡𝐚𝐬𝐞 𝟏 𝐟𝐨𝐥𝐥𝐨𝐰-𝐮𝐩 𝐝𝐚𝐭𝐚 𝐟𝐨𝐫 𝐢𝐧𝐝𝐢𝐯𝐢𝐝𝐮𝐚𝐥𝐢𝐳𝐞𝐝 𝐦𝐑𝐍𝐀 𝐜𝐚𝐧𝐜𝐞𝐫 𝐯𝐚𝐜𝐜𝐢𝐧𝐞 𝐜𝐚𝐧𝐝𝐢𝐝𝐚𝐭𝐞 𝐬𝐡𝐨𝐰 𝐝𝐞𝐥𝐚𝐲𝐞𝐝 𝐭𝐮𝐦𝐨𝐫 𝐫𝐞𝐜𝐮𝐫𝐫𝐞𝐧𝐜𝐞 +++ We believe that therapeutic #mRNA cancer vaccines tailored to the individual mutations of a patient’s tumor, called neoantigens, may have the potential to prevent cancer from coming back in early stages of the disease. 𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐧𝐞𝐞𝐝 Cancers in early disease stages are regularly treated by removing the tumor surgically. The standard of care foresees regular check-ups to see if the cancer comes back, known as “watchful waiting”.[1] Many cancers progress in such a way that the patient initially appears tumor-free after surgery, but after some time small amounts of cancer cells that were initially invisible after surgery may grow and form metastases meaning a poor prognosis for the patient. We have been evaluating individualized neoantigen-specific cancer vaccine candidates since the start of the first clinical trial based on our uridine mRNA-LPX technology in 2014. 𝐍𝐞𝐰 𝐝𝐚𝐭𝐚 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐚𝐭 #𝐀𝐀𝐂𝐑𝟐𝟒 𝐚𝐧𝐧𝐮𝐚𝐥 𝐦𝐞𝐞𝐭𝐢𝐧𝐠: Three-year follow-up data from an investigator-initiated Phase 1 clinical trial with our mRNA-based individualized neoantigen-specific cancer vaccine candidate autogene cevumeran (#BNT122) show that the candidate elicited an immune response up to three years post administration and delayed tumor recurrence in some patients with resected pancreatic cancer (#PDAC). Autogene cevumeran is being jointly developed by BioNTech and Genentech, a member of the Roche Group. A randomized Phase 2 trial is ongoing with the aim to investigate whether these findings can also be found in a lager patient population with PDAC. 𝐅𝐥𝐢𝐩 𝐭𝐡𝐫𝐨𝐮𝐠𝐡 𝐭𝐡𝐞 𝐤𝐞𝐲 𝐟𝐢𝐧𝐝𝐢𝐧𝐠𝐬 𝐩𝐫𝐞𝐬𝐞𝐧𝐭𝐞𝐝 𝐚𝐭 𝐀𝐀𝐂𝐑𝟐𝟒 𝐚𝐧𝐧𝐮𝐚𝐥 𝐦𝐞𝐞𝐭𝐢𝐧𝐠 𝐛𝐲 𝐨𝐮𝐫 𝐜𝐨𝐥𝐥𝐞𝐚𝐠𝐮𝐞𝐬 𝐟𝐫𝐨𝐦 Memorial Sloan Kettering Cancer Center: 👇 𝐑𝐞𝐚𝐝 𝐦𝐨𝐫𝐞: https://lnkd.in/eKZT8bae [1] National Cancer Institute. Pancreatic Cancer Treatment (PDQ®)–Patient Version. https://lnkd.in/eU9xBAJZ

+++ 𝐌𝐞𝐞𝐭 𝐁𝐢𝐨𝐍𝐓𝐞𝐜𝐡’𝐬 𝐩𝐢𝐨𝐧𝐞𝐞𝐫𝐬: 𝐕𝐚𝐥𝐞𝐬𝐤𝐚 𝐒𝐜𝐡𝐢𝐥𝐥𝐢𝐧𝐠 +++ “At BioNTech my favorite moments are when the team decides to do what’s best. Not what’s easiest or least work. Best for the process, best for the patient,” describes Valeska Schilling the culture that prevails at #TeamBioNTech. With this ethos, we are driving the development of our personalized product candidates and aim to achieve product approvals in ten oncological indications by 2030.  𝐁𝐮𝐢𝐥𝐝𝐢𝐧𝐠 𝐜𝐨𝐦𝐦𝐞𝐫𝐜𝐢𝐚𝐥 𝐦𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 𝐜𝐚𝐩𝐚𝐜𝐢𝐭𝐢𝐞𝐬 𝐟𝐨𝐫 𝐩𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐳𝐞𝐝 𝐜𝐚𝐧𝐜𝐞𝐫 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞𝐬  As Senior Director and Site Head, Valeska is responsible for setting up the pilot facility, our first commercial-scale manufacturing site for mRNA-based individualized cancer medicines close to our headquarters in Mainz. The pilot facility will provide BioNTech with additional capacities as we aim to develop and manufacture our investigational mRNA cancer vaccines at scale - initially through additional clinical manufacturing capacity and ultimately through the possibility of commercial-scale manufacturing, pending regulatory approval. The pilot facility team is growing across different departments and functions. Become part of #TeamBioNTech and join us in making decisions that bring us closer to achieving our mission of improving the health of many patients around the globe. 𝑫𝒊𝒔𝒄𝒐𝒗𝒆𝒓 𝒐𝒑𝒆𝒏 𝒑𝒐𝒔𝒊𝒕𝒊𝒐𝒏𝒔 𝒂𝒕 𝒕𝒉𝒆 𝒑𝒊𝒍𝒐𝒕 𝒇𝒂𝒄𝒊𝒍𝒊𝒕𝒚: https://lnkd.in/dg49yN5S  

+++ 𝗙𝗬 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝟮𝟬𝟮𝟯 𝗮𝗻𝗱 𝗰𝗼𝗿𝗽𝗼𝗿𝗮𝘁𝗲 𝘂𝗽𝗱𝗮𝘁𝗲 +++ 2023 was another successful year in our journey aiming to develop novel therapies to address cancer and infectious diseases. Some highlights: 🏆 We maintained a leading position in the global COVID-19 vaccine market. 🔬 We grew and advanced our late-stage pipeline. 📊 We again delivered a strong financial performance. 𝗪𝗵𝗮𝘁 𝘁𝗼 𝗲𝘅𝗽𝗲𝗰𝘁 𝗶𝗻 𝟮𝟬𝟮𝟰: This year will be a transition year for our company during which we will continue to invest in our long-term growth strategy, while maintaining strict cost discipline. We look forward to welcoming Annemarie Hanekamp to the Management Board and #TeamBioNTech. She will join us as Chief Commercial Officer effective July 1, 2024. 𝗢𝘂𝘁𝗹𝗼𝗼𝗸: We believe our investments and efforts will pave the way for an initial wave of oncology product launches from 2026 onwards. 𝗟𝗶𝗻𝗸 𝘁𝗼 𝗣𝗥 𝗮𝗻𝗱 𝗳𝗼𝗿𝘄𝗮𝗿𝗱-𝗹𝗼𝗼𝗸𝗶𝗻𝗴 𝘀𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁𝘀: https://lnkd.in/eMyh6iyq

🔬 𝐁𝐢𝐨𝐍𝐓𝐞𝐜𝐡 𝐚𝐭 #𝐀𝐀𝐂𝐑𝟐𝟎𝟐𝟒 We look forward to presenting updates for selected personalized #mRNA and targeted ADC #oncology candidates at the AACR Annual Meeting 2024 in San Diego, USA. This year’s data show how we’re delivering on our commitment of investigating novel treatment approaches to patients.   𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬 𝐢𝐧𝐜𝐥𝐮𝐝𝐞: 𝐈𝐧𝐝𝐢𝐯𝐢𝐝𝐮𝐚𝐥𝐢𝐳𝐞𝐝 𝐦𝐑𝐍𝐀-𝐛𝐚𝐬𝐞𝐝 𝐢𝐦𝐦𝐮𝐧𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬: longer-term follow-up data of activity and immune responses of the investigator-initiated first-in-human Phase 1 trial with our mRNA-based individualized neoantigen-specific immunotherapy (iNeST) candidate autogene cevumeran (BNT122, RO7198457) in patients with resected pancreatic ductal adenocarcinoma (PDAC) 𝐎𝐟𝐟-𝐭𝐡𝐞-𝐬𝐡𝐞𝐥𝐟 𝐦𝐑𝐍𝐀-𝐛𝐚𝐬𝐞𝐝 𝐢𝐦𝐦𝐮𝐧𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬: preliminary results on the LuCa-MERIT-1 Phase 1 trial with our off-the-shelf, shared tumor-associated-antigen-based mRNA therapeutic cancer vaccine candidate BNT116 in combination with docetaxel in patients with advanced unresectable or metastatic non-small cell lung cancer (NSCLC) 𝐓𝐚𝐫𝐠𝐞𝐭𝐞𝐝 𝐚𝐧𝐭𝐢𝐛𝐨𝐝𝐲-𝐝𝐫𝐮𝐠 𝐜𝐨𝐧𝐣𝐮𝐠𝐚𝐭𝐞𝐬 (𝐀𝐃𝐂𝐬): trial in progress poster on our global Phase 1/2a trial of the #ADC candidate BNT324/DB-1311 targeting the immune checkpoint protein B7H3 in patients with pretreated advanced or metastatic solid tumors The full abstracts are available on the AACR Annual Meeting website. Further information on BioNTech’s pipeline candidates can be found on our website. 𝐑𝐞𝐚𝐝 𝐦𝐨𝐫𝐞:

+++𝗣𝗹𝗮𝗻𝗻𝗲𝗱 𝗥𝗲𝘁𝗶𝗿𝗲𝗺𝗲𝗻𝘁 𝗼𝗳 𝗼𝘂𝗿 𝗖𝗖𝗢 & 𝗖𝗕𝗢 𝗦𝗲𝗮𝗻 𝗠𝗮𝗿𝗲𝘁𝘁+++  After more than a decade of serving as Board Member in different roles, Sean Marett will retire this year as planned. A new CCO will be announced by the end of March 2024. His responsibilities as CBO are being gradually transferred to James Ryan, Ph.D., Chief Legal Officer who will also take on the role as BioNTech’s CBO at the end of the transition phase and upon Sean Marett’s retirement. As of July 1, 2024, Sean Marett will continue as a specialist advisor at least until the end of the year.        👏 Sean's contributions to BioNTech's business development, fund-raising, and commercial activities have been crucial to our transformation into a next-generation immunotherapy company. Here are just a few of his accomplishments:     ● Various financing activities to ensure liquidity of over $1 billion, the largest Series A financing round for a biotech company at that stage worldwide. The activities were especially important for us in the first decade when we were a private company with pre-clinical programs.     ● Revenue-generating research and development agreements which Sean and his teams negotiated with high-profile pharmaceutical companies.     ● Complex global licensing and M&A transactions and strategic partnerships Sean and his teams reached with multiple governments, academic institutions, and charitable foundations.   ● Several supply agreements for our first product with governments.     ● The commercialization of the Pfizer-BioNTech COVID-19 Vaccine in Germany and Türkiye.     Without Sean's determination, drive, and experience in aligning all stakeholders towards a common goal, BioNTech would not be the innovative company it is today. We're excited to see what the future holds with our new CCO, who will be announced by the end of March 2024.     We’d like thank Sean in the name of the BioNTech family with a photo from your early days at BioNTech! #throwbackthursday     https://lnkd.in/e-tuE25M